Rituximab activates Syk and AKT in CD20-positive B cell lymphoma cells dependent on cell membrane cholesterol levels

Experimental Hematology

Volumn 41, Issue 8, 2013, Pages 687-696.e1

  Nozaki, Yumi ^a   Mitsumori, Toru ^a   Yamamoto, Takeo ^a   Kawashima, Ichiro ^a   Shobu, Yuki ^a   Hamanaka, Satoshi ^a   Nakajima, Kei ^a   Komatsu, Norio ^b   Kirito, Keita ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CHOLESTEROL; DOXORUBICIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE SYK; RITUXIMAB; SIMVASTATIN;

ADULT; AGED; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CELL LEVEL; CELL MEMBRANE; CELL MEMBRANE CHOLESTEROL LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LIPID RAFT; LYMPHOMA CELL; MALE; PRIORITY JOURNAL;

EID: 84880715051     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.04.006     Document Type: Article

References (38)

1. Terui Y., Mishima Y., Sugimura N., et al. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma. Clin Cancer Res 2009, 15:2523-2530.
2. Hiraga J., Tomita A., Sugimoto T., et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 2009, 113:4885-4893.
3. Bezombes C., Fournie J.J., Laurent G. Direct effect of rituximab in B-cell-derived lymphoid neoplasias: mechanism, regulation, and perspectives. Mol Cancer Res 2011, 9:1435-1442.
4. Jazirehi A.R., Vega M.I., Chatterjee D., Goodglick L., Bonavida B. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by rituximab. Cancer Res 2004, 64:7117-7126.
5. Vega M.I., Jazirehi A.R., Huerta-Yepez S., Bonavida B. Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-κB activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. J Immunol 2005, 175:2174-2183.
6. Jazirehi A.R., Huerta-Yepez S., Cheng G., Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-κB signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005, 65:264-276.
7. Suzuki E., Umezawa K., Bonavida B. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene 2007, 26:6184-6193.
8. Jazirehi A.R., Vega M.I., Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 2007, 67:1270-1281.
9. Uddin S., Hussain A.R., Siraj A.K., et al. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006, 108:4178-4186.
10. Hasselblom S., Hansson U., Olsson M., et al. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Br J Haematol 2010, 149:560-568.
11. Katoh S.-Y., Kamimoto T., Yamakawa D., Takakura N. Lipid rafts serve as signaling platforms for Tie2 receptor tyrosine kinase in vascular endothelial cells. Exp Cell Res 2009, 315:2818-2823.
12. Zhuang L., Kim J., Adam R.M., Solomon K.R., Freeman M.R. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005, 115:959-968.
13. Deans J.P., Robbins S.M., Polyak M.J., Savage J.A. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J Biol Chem 1998, 273:344-348.
14. Semac I., Palomba C., Kulangara K., et al. Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res 2003, 63:534-540.
15. Walshe C.A., Beers S.A., French R.R., et al. Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling. J Biol Chem 2008, 283:16971-16984.
16. Kheirallah S., Caron P., Gross E., et al. Rituximab inhibits B-cell receptor signaling. Blood 2010, 115:985-994.
17. Hu Y., Kirito K., Yoshida K., et al. Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan. Mol Cancer Ther 2009, 8:2329-2338.
18. Vega M.I., Huerta-Yepez S., Martinez-Paniagua M., et al. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. Clin Cancer Res 2009, 15:6582-6594.
19. Cragg M.S., Morgan S.M., Chan H.T., et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003, 101:1045-1052.
20. Deans J.P., Kalt L., Ledbetter J.A., Schieven G.L., Bolen J.B., Johnson P. Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20. J Biol Chem 1995, 270:22632-22638.
21. Popoff I.J., Savage J.A., Blake J., Johnson P., Deans J.P. The association between CD20 and Src-family tyrosine kinases requires an additional factor. Mol Immunol 1998, 35:207-214.
22. Cuevas B., Lu Y., Watt S., et al. SHP-1 regulates Lck-induced phosphatidylinositol 3-kinase phosphorylation and activity. J Biol Chem 1999, 274:27583-27589.
23. Inabe K., Kurosaki T. Tyrosine phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is required for Akt activation in response to CD19 engagement. Blood 2002, 99:584-589.
24. Beitz L.O., Fruman D.A., Kurosaki T., Cantley L.C., Scharenberg A.M. SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling. J Biol Chem 1999, 274:32662-32666.
25. Pogue S.L., Kurosaki T., Bolen J., Herbst R. B cell antigen receptor-induced activation of Akt promotes B cell survival and is dependent on Syk kinase. J Immunol 2000, 165:1300-1306.
26. Moon K.D., Post C.B., Durden D.L., et al. Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase. J Biol Chem 2005, 280:1543-1551.
27. Schymeinsky J., Then C., Sindrilaru A., et al. Syk-mediated translocation of PI3Kδ to the leading edge controls lamellipodium formation and migration of leukocytes. PLoS One 2007, 2:e1132.
28. Qiao Q., Nozaki Y., Sakoe K., Komatsu N., Kirito K. NF-kappaB mediates aberrant activation of HIF-1 in malignant lymphoma. Exp Hematol 2010, 38:1199-1208.
29. Bezombes C., Grazide S., Garret C., et al. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 2004, 104:1166-1173.
30. Hammadi M., Youinou P., Tempescul A., et al. Membrane microdomain sphingolipids are required for anti-CD20-induced death of chronic lymphocytic leukemia B cells. Haematologica 2012, 97:288-296.
31. Meyer zum Buschenfelde C., Feuerstacke Y., Gotze K.S., Scholze K., Peschel C. GM1 expression of non-Hodgkin's lymphoma determines susceptibility to rituximab treatment. Cancer Res 2008, 68:5414-5422.
32. Winiarska M., Bil J., Wilczek E., et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 2008, 5:e64.
33. Wu H., Jiang H., Lu D., et al. Effect of simvastatin on glioma cell proliferation, migration, and apoptosis. Neurosurgery 2009, 65:1087-1096.
34. Jeon J.H., Kim S.K., Kim H.J., Chang J., Ahn C.M., Chang Y.S. Lipidraft modulation inhibits NSCLC cell migration through delocalization of the focal adhesion complex. Lung Cancer 2010, 69:165-171.
35. Raghu H., Sodadasu P.K., Malla R.R., Gondi C.S., Estes N., Rao J.S. Localization of uPAR and MMP-9 in lipid rafts is critical for migration, invasion and angiogenesis in human breast cancer cells. BMC Cancer 2010, 10:647.
36. Ennishi D., Asai H., Maeda Y., et al. Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 2010, 21:1217-1221.
37. Nowakowski G.S., Maurer M.J., Habermann T.M., et al. Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol 2010, 28:412-417.
38. Xuan Koo Y., Tan D.S.W., Tan I.B.H., et al. Effect of concomitant statin, metformin, or aspirin on rituximab treatment for diffuse large B-cell lymphoma. Leuk Lymphoma 2011, 52:1509-1516.